Engineered T cell–agonist chimera for logic-gated STING activation and augmented cancer immunotherapy
Proceedings of the National Academy of Sciences · 10.11.2026 · 123 (45)
DOI: 10.1073/pnas.2617384123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 03.11.2026. Verfasst von Fangmin Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Chemical Biology and Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201…. Hauptthemen laut MEDLINE: Membrane Proteins, T-Lymphocytes, Immunotherapy, Adoptive, Neoplasms. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China (MOST), MOST | National Natural Science Foundation of China (NSFC), China Postdoctoral Science Foundation ().
Abstract (Originalsprache)
The efficacy of adoptive T cell therapy against solid tumors is markedly hindered by the immunosuppressive microenvironment. Here, we demonstrate that stimulator of interferon genes (STING) activation in tumor-associated macrophages (TAM) enhances the intratumoral infiltration and cytotoxicity of adoptive T cells. We next design a TAM-targeted nanoagonist and engineer a T cell – agonist chimera (SNTC) via covalent surface anchoring, to achieve synchronized biodistribution of STING agonist with adoptive T cells. The nanoagonist is locally released in tumor tissue in response to the elevated reduction potential on T cell surface, followed by intracellular glutathione-mediated restoration of STING agonist in TAM, thereby enabling AND logic-gated STING activation. SNTC not only reshapes tumor stroma and immunosuppressive tumor microenvironment to augment adoptive T cell function but also enhances the antigen presentation ability of TAM to activate endogenous T cells. SNTC elicits robust antitumor efficacy in melanoma tumor-bearing mice, resulting in over 40% survival beyond 60 d. Moreover, combining tumor-infiltrating T lymphocyte (TIL)-based SNTC with immune checkpoint blockade therapy leads to sustained tumor regression in mouse model of orthotopic pancreatic tumor. Collectively, SNTC holds translational potential to optimize STING activation for adoptive T cell therapy of cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Chemical Biology and Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China.
- Department of Pharmaceutics, School of Pharmacy, Jilin University, Changchun 130021, China.
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
- School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200241, China.
Förderung
- Ministry of Science and Technology of the People's Republic of China (MOST)
- MOST | National Natural Science Foundation of China (NSFC)
- China Postdoctoral Science Foundation ()
- Ministry of Science and Technology of the People’s Republic of China
Zitieren
APA
Chen, F., Li, M., Ren, S., Huang, L., Lan, W., Wu, Q., Hou, B., Chen, C., Xu, Z., & Yu, H. (2026). Engineered T cell–agonist chimera for logic-gated STING activation and augmented cancer immunotherapy. Proceedings of the National Academy of Sciences, 123(45). https://doi.org/10.1073/pnas.2617384123
Vancouver
Chen F, Li M, Ren S, Huang L, Lan W, Wu Q, et al. Engineered T cell–agonist chimera for logic-gated STING activation and augmented cancer immunotherapy. Proceedings of the National Academy of Sciences. 2026;123(45). doi:10.1073/pnas.2617384123
BibTeX
@article{Chen2026,
author = {Chen, Fangmin and Li, Mengfan and Ren, Siyuan and Huang, Lujia and Lan, Wenyue and Wu, Qilong and Hou, Bo and Chen, Chang and Xu, Zhiai and Yu, Haijun},
title = {Engineered T cell–agonist chimera for logic-gated STING activation and augmented cancer immunotherapy},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {45},
doi = {10.1073/pnas.2617384123}
}
EUVIMED